Update on human immunodeficiency virus (HIV)-2 infection

Clinical Infectious Diseases

Volumn 52, Issue 6, 2011, Pages 780-787

  Campbell Yesufu, Omobolaji T ^a   Gandhi, Rajesh T ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; DARUNAVIR PLUS RITONAVIR; ELVITEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC TEST; DRUG MONITORING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; TREATMENT RESPONSE; VIRUS TRANSMISSION; WESTERN BLOTTING;

ANTI-HIV AGENTS; HIV INFECTIONS; HIV-2; HUMANS;

EID: 79953733544     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq248     Document Type: Article

References (71)

1. Centers for Disease Control. Factsheet HIV Type 2. Available at: http://wonder.cdc.gov/wonder/prevguid/m0038078/m0038078.asp. Accessed 24 June 2010.
2. Gottlieb GS, Eholié SP, Nkengasong J, et al. A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa. AIDS 2008; 22:2069.
3. da Silva Z, Oliveira I, Andersen A, et al. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing? AIDS 2008; 22:1195-202.
4. van der Loeff MF, Awasana A, Sarge-Njie R, et al. Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2. Int J Epidemiol 2006; 35:1322-28. (Pubitemid 44605560)
5. van Tienen C, van der Loeff MS, Zaman S, et al. Two distinct epidemics: the rise of HIV-1 and decline of HIV-2 infection between 1990 and 2007 in rural Guinea-Bissau. J Acquir Immune Defic Syndr 2010; 53:640-7.
6. de Silva T, Cotton M. Rowland-Jones S HIV-2: the forgotten AIDS virus. Trends Microbiol 2008; 16:588-95.
7. Soriano V, Gomes P, Heneine W, et al. Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. J Med Virol 2000; 61:111-6. (Pubitemid 30191235)
8. Torian L, et al. HIV Type 2 in New York City, 2000-2008. CID 2010; 51:1334-42.
9. Barin F, Cazein F, Lot F, et al. Prevalence of HIV-2 and HIV-1 group O infections among new HIV diagnoses in France: 2003-2006. AIDS 2007; 21:2351-53. (Pubitemid 350287466)
10. Centers for Disease Control. Epidemiologic notes and reports AIDS due to HIV-2 infection-New Jersey. MMWR Morb Mortal Wkly Rep 1988; 37:33-5.
11. US Census 2000 Report. Available at: http://www.census.gov/population/ www/socdemo/foreign/STP-159-2000tl.html. Accessed 24 June 2010.
12. Smith J. Cape Verde, rising, with emigres' help; deepening ties bind islands, Bay State. Available at: http://www.boston.com/news/local/ massachusetts/articles/2009/04/26/cape-verde-rising-with-emigres-help/?page52. The Boston Globe April 26 2009. Accessed 24 June 2010
13. Kent MM. Immigration, and America's black population. Vol 62. Population Bulletin, 2007: 13. Available at: http://www.prb.org/pdf07/62.4immigration.pdf Accessed 24 June 2010.
14. Settegren A. History of Ghanaians in Chicago. http://www. chicagosistercities. com/cities/h-accra.php. Accessed 24 June 2010.
15. Kanki P, Travers K, Mboup S, et al. Slower heterosexual spread of HIV- 2 than HIV-1. Lancet 1994; 343:943-6. (Pubitemid 24117229)
16. Adjorlolo-Johnson G, De Cock K, Ekpini E, et al. Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA 1994; 272:462-6. (Pubitemid 24235696)
17. O'Donovan D, Ariyoshi K, Milligan P, et al. Maternal plasma viral RNA levels determine marked differences in mother-to-child transmission rates of HIV-1 and HIV-2 in the Gambia. AIDS 2000; 14:441-8. (Pubitemid 30182442)
18. Popper S, Sarr A, Travers K, et al. Lower Human Immunodeficiency Virus (HIV) Type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis 1999; 180:1116-21. (Pubitemid 30070194)
19. Marlink R, Kanki P, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265:1587-90. (Pubitemid 24308975)
20. MacNeil A, Sarr A, Sankale J, Meloni S, Mboup S, Kanki P. Direct evidence of lower viral replication rates in vivo in Human Immunodeficiency Virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol 2007; 81:5325-30. (Pubitemid 46744441)
21. Berry N, Jaffar S, van der Loeff M, et al. Low level viremia and high CD4% predict normal survival in a cohort of HIV Type-2-infected villagers. AIDS Res and Human Retroviruses 2002; 18:1167-73. (Pubitemid 35370604)
22. van der Loeff MF, Larke N, Kaye S, et al. Vndetectable plasma viral load predicts normal survival in HIV-2 infected people in a West African village. Retrovirology 2010; 7:46.
23. Andersson S, Norregren H, da Silva Z, et al. Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea- Bissau,West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. Arch Intern Med 2000; 160: 3286-93.
24. Schimm van der Loeff M, Jaffar S, Aveika AA, et al. Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in the Gambia. AIDS 2002; 16:1775-83.
25. Hanson A, Sarr A, Shea A, et al. Distinct profile of T cell activation in HIV type 2 compared to HIV type 1 infection: differential mechanism for immunoprotection. AIDS Res Hum Retroviruses 2005; 21:791-8. (Pubitemid 41434184)
26. Michel P, Balde A, Roussilhon C, Aribot G, Sarthou JL, Gougeon ML. Reduced immune activation and T cell apoptosis in human immunodeficiency virus type 2 compared with type1: correlation of T cell apoptosis with of b2-microglobulin concentration and disease evolution. J Infect Dis 2000; 181:64-75. (Pubitemid 30049034)
27. Leligdowicz A, Feldman J, Jaye A, et al. Direct relationship between virus load and systemic immune activation in HIV-2 infection. J Infect Dis 2010; 201:114-22.
28. Schindler M, Münch J, Kutsch O, et al. Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 2006; 125:1055-67. (Pubitemid 43884762)
29. Travers K, Mboup S, Marlink R, et al. Natural protection against HIV-1 infection provided by HIV-2. Science 1995; 268:1612-15.
30. Kokkotou E, Sankale JL, Mani I, et al. In vitro correlates of HIV-2 mediated HIV-1 protection. Proc Natl Acad Sci USA 2000; 97:6797-802. (Pubitemid 30412794)
31. Wiktor S, Nkengasong J, Ekpini E, et al. Lack of protection against HIV- 1 infection among women with HIV-2 infection. AIDS 1999; 13:695-9. (Pubitemid 29286704)
32. Schim van der Loeff M, Aaby P, Aryioshi K, et al. HIV-2 does not protect against HIV-1 infection in a rural community in Guinea-Bissau. AIDS 2001; 15:2303-10. (Pubitemid 34059838)
33. Norregren H, Andersson S, Biague A, et al. Trends and interaction of HIV-1 and HIV-2 in Guinea-Bissau, West Africa: no protection of HIV-2 against HIV-1 infection. AIDS 1999; 13:701-7. (Pubitemid 29286705)
34. Greenberg A. Possible protective effect of HIV-2 against incident HIV- 1 infection: review of available epidemiological and in vitro data. AIDS 2001; 15:2319-21. (Pubitemid 34059841)
35. Matheron S, Pueyo S, Damond F, et al. Factors associated with clinical progression in HIV-2 infected patients. AIDS 2003; 17:2593-601. (Pubitemid 38402337)
36. Bienaime A, Colson P, Moreau J, Zandotti C, Pellissier J-F, Brouqui P. Progressive multifocal leukoencephalopathy in HIV-2 infected patient. AIDS 2006; 20:1342-43. (Pubitemid 44030390)
37. Stoner GL, Agostini HT, Ryschkewitch CF et al. Detection of JC virus in two African cases of progressive multifocal leukoencephalopathy including identification of JCV type 3 in a Gambian AIDS patient. J Med Microbiol 1998; 47:733-42. (Pubitemid 28342822)
38. Rubsamen-Waigman H, Adamski M, Von Briesen H. Lethal progressive multifocal leukoencephalopathy in an HIV 2 infected person as the only AIDS manifestation. AIDS Forsch 1987; 2:572-5.
39. Martinez-Steel E, Awasana A, Corrah T, et al. Is HIV-2-induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic. AIDS 2007; 21:317-24. (Pubitemid 46175044)
40. Calado S, Canas N, Viana-Baptista M, Ribeiro C, Mansinho K. Multiple cranial neuropathy and HIV-2. J Neurol Neurosurg Psychiatry 2004; 75:660-1. (Pubitemid 38406677)
41. Torres JR, Torres-Viera MA, Schupbach J, Rangel HR, Pujol FH. Nonimmune thrombocytopenia responsive to antriretroviral therapy and HIV-2 infection. J Infect 2007; 54:e21-4. (Pubitemid 44939360)
42. Moulignier A, Lascoux C, Bourgarit A. HIV type 2 demyelinating encephalomyelitis. Clin Infect Dis 2006; 42:e89-91.
43. Shahinian V, Rajaraman S, Borucki M, Grady J, Hollander WM, Ahuja TS. Prevalence of HIV-associated nephropathy in autopsies of HIVinfected patients. Am J Kidney Dis 2000; 35:884-8. (Pubitemid 30238201)
44. Izzedine H, Damond F, Brocheriou I, Ghosn J, Lassal H, Deray G. HIV-2 infection and HIV-associated nephropathy. AIDS 2006; 20:949-58.
45. Greenwald J, Burstein G, Pincus J, Branson B. A rapid review of rapid HIV antibody tests. Curr Infect Dis Rep 2006; 8:125-31.
46. Roche Amplicor HIV-1 Monitor Test Summary. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ ApprovedProducts/PremarketApprovalsPMAs/UCM093319.pdf.
47. Rodés B, Sheldon J, Toro C, et al. Quantitative detection of plasma HIV type 2 subtype A RNA by the Nuclisens Easy Q Assay (version 1.1). J Clin Microbiol 2007; 45:88-92. (Pubitemid 46106411)
48. Panel on Antiretroviral Guidelines for Adults, and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, 2009: Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL. pdf. Accessed 24 June 2010.
49. Prise en Charge Médicale des Personnes Infectées par le VIH Ministry of Health France, 2008. http://www.sante-sports.gouv.fr/IMG/pdf/ Recommandations-du-groupe-d-experts-2008-Points-forts-et-recommandations.pdf. Accessed 24 June 2010.
50. Ntemgwa ML, Toni T, Brenner B, Camacho R, Wainberg W. Antiretroviral drug resistance in human immunodeficiency virus type Antimicrob Agents Chemother 2009; 53:3611-19.
51. Ruelle J, Sanou M, Liu H, Vandenbroucke A, Duquenne A, Goubau P. Genetic polymorphisms and resistance mutations Of HIV type 2 in antiretroviral-naive patients in Burkina Faso. AIDS Res Hum Retroviruses 2007; 23:955-64. (Pubitemid 47492335)
52. Ruelle J, Roman F, Vandenbroucke A, et al. Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database. BMC Infect Dis 2008; 8:21.
53. Brower ET, Bacha UM, Kawasaki Y, Freire E. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des 2008; 71:298-305. (Pubitemid 351347797)
54. Desbois D, Roquebert D, Peytavin G, et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 2008; 52:1545-8. (Pubitemid 351522031)
55. Witvrouw M, Pannecouque C, SwitzerWM, et al. Susceptibility of HIV- 2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004; 9:57-65. (Pubitemid 38313948)
56. Roquebert B, Damond F, Collin G et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 2008; 62:914-20.
57. Matheron S. HIV-2 infection: a call for controlled trials. AIDS 2008; 22:2073-4.
58. Benard A, Damond F, Campa P, et al. Good response to lopinavir/ritonavir- containing antiretroviral regimens in antiretroviral-näve HIV-2 infected patients. AIDS 2009; 23:1171-179.
59. van der Ende M, Prins J, Brinkman K, et al. Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2 infected patients. AIDS 2003 Jul;17 (Suppl 3):S55-61. (Pubitemid 36951670)
60. Adje-Toure C, Cheingsong R, Garcia-Lerma J, et al. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD41 cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS 2003; 17(Suppl 3):S49-54. (Pubitemid 36951669)
61. World Health Organization. 2010 Guidelines on antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. Available at: http://whqlibdoc.who.int/publications/2010/ 9789241599764-eng.pdf. Accessed 24 August 2010.
62. Matheron S, Damond F, Benard A, et al. CD4 cell recovery in treated HIV-2 infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort. AIDS 2006; 20:459-62.
63. Drylewicz J, Matheron S, Lazaro E, et al. Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. AIDS 2008; 22:457-68. (Pubitemid 351317287)
64. Descamps D, Damond F, Matheron S, et al. High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen. J Med Virol 2004; 74:197-201. (Pubitemid 39150384)
65. Hawkins C, Chaplin B, Idoko J, et al. Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first line antiretroviral therapy in Nigeria. J Acquir Immune Defic Syndr 2009; 52:228-34.
66. Salgado M, Toro C, Simón A, et al. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. J Clin Virol 2009; 46:173-5.
67. Gottlieb G, Badiane N, Hawes S, et al. Emergence of multiclass drugresistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resource-limited West Africa. Clin Infect Dis 2009; 48:476-83.
68. Damond F, Lariven S, Roquebert B, et al. Virological and immunogical response to HAART regimen containing integrase inhibitors in HIV-2- infected patients. AIDS 2008; 22:665-6. (Pubitemid 351640604)
69. Landman R, Damond F, Gerbe J, Brun-Vezinet F, Yeni P, Matheron S. Immunovirological and therapeutic follow up of HIV-1/HIV-2 dually seropositive patients. AIDS 2009; 23:423-43.
70. Rodés B, Toro C, Jiménez V, Soriano V. Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2. Clin Infect Dis 2005; 41:e19-21.
71. Gilleece Y, Chadwick DR, Breuer J, Hawkins D, Smit E, McCrae LX, Pillay D, Smith N, Anderson J; BHIVA Guidelines Subcommittee. British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010. HIV Med. 11:611-9.